Palo Alto, CA, United States
Palo Alto, CA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | May 16, 2017
Site: www.businesswire.com

PALO ALTO, Calif.--(BUSINESS WIRE)--Symphony Communication Services, LLC today announced it has raised $63 million in new capital to accelerate global adoption, propel platform innovation and expand into new markets. BNP Paribas led the round, along with additional investment by a majority of Symphony’s existing shareholders. Symphony previously raised a total of $170 million from the world’s leading financial firms, venture capital firms, and Google. Symphony enables businesses to provide best-of-breed collaboration technology to their employees, while driving efficiency and ensuring security and compliance. Enterprise customers can now centralize all workflow in a single platform, using Symphony as a replacement for traditional email and voice systems to securely communicate with internal and external teams, share documents and content, and conduct meetings with conferencing and screen-sharing. Symphony’s success is a direct result of its powerful platform, customizable user experience, and open partner ecosystem which delivers a large and growing market of applications and integrations. User adoption has organically spread at the world’s top companies as the platform’s hundreds of thousands of licensed paying users have validated its benefits. Symphony customers are able streamline and automate workflows through the use of integrated applications and bots, dramatically improving the way professionals engage with colleagues, clients and workflow applications. Symphony accelerates business, drives productivity, and delivers a more engaging client experience. “We are thrilled to have the support of our new and existing investors as we accelerate global platform adoption,” said David Gurlé, founder and CEO of Symphony. “This financing is a recognition of the value our customers have experienced as the Symphony community has grown. Our customers’ desire to make Symphony their central platform and replace legacy tools is an endorsement of the efficiencies brought by an integrated collaboration platform and streamlined workflow.” “Digital transformation is central to BNP Paribas Global Markets’ strategy, and collaboration with fintechs is a crucial part of that process. Forming agile partnerships with exciting and innovative companies like Symphony helps us deliver an exceptional service to clients, and remain their partner of choice in a changing world,” said Olivier Osty, Executive Head of Global Markets, BNP Paribas. Symphony will use the new capital to accelerate expansion, to drive growth in both its current and new markets, and further build out its feature stack to deliver a new wave of innovation to enterprises and replace traditional collaboration tools. Symphony is the cloud-based messaging and collaboration platform that connects markets, organizations and individuals, securely. Powered by an open and growing app ecosystem, and protected with customer-owned encryption keys, Symphony’s communication platform increases workflow productivity while maintaining global regulatory compliance. Already the platform of choice for the financial services industry, Symphony eliminates inefficient workflows to boost productivity in information-driven businesses. Founded in October 2014 and headquartered in Palo Alto, CA, the company has offices in New York, Hong Kong, Singapore and London. To sign up for Symphony, find out more about the company and keep up on the latest news, visit www.symphony.com and follow @Symphony.


Patent
Symphony | Date: 2012-07-03

The present invention provides compounds useful for inhibiting the ADAM-10 protein, with selectivity versus MMP-1. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role.


Patent
Symphony | Date: 2014-03-21

The present invention provides compounds useful for inhibiting the ADAM-10 protein, with selectivity versus MMP-1. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role.


Patent
Symphony | Date: 2015-09-04

The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include spectrum selective kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.


Patent
Symphony | Date: 2012-03-14

The present invention provides compounds useful for inhibiting the ADAM-10 protein, with selectivity versus MMP-1. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role.


Patent
Symphony | Date: 2015-01-14

A method for controlling the parallelism of first and second surfaces that define an optically resonant cavity is disclosed. The surfaces are separated by a first separation that is based on a support that holds the first surface relative to the second surface. The support comprises a first material and includes one or more regions in which the material stress of the first material is heat tuned to locally induce a stress gradient that results in a localized deformation. By controlling the locations and amounts of one or more localized deformation regions, the orientation of the first surface relative to the second surface is controlled.


The present invention provides a method and apparatus for separating rubber components and metal components of tread portions of road vehicle tyres. Each tread portion comprises a tread side and a back side, and the method comprising the steps: forming a chain of tread portions by connecting a plurality of tread portions in a longitudinal direction, said tread portions being connected such that the tread side of each tread portion faces in the same direction, such that the chain of tread portions comprises a tread side and a back side; causing the tread side of at least a part of the chain of tread portions to contact a curved surface; and directing at least one high-pressure jet against the back side of the part of the chain of tread portions contacting the curved surface, to cause separation of the rubber components from the metal components. In a preferred arrangement the at least one high-pressure jet is at least one ultra high-pressure water jet. An apparatus is provided to perform the method.


Patent
Symphony | Date: 2014-08-06

In an open environment, a consensus building means for maintaining dependability throughout the entire life cycle of a target system between stakeholders is provided, thereby appropriately operating the target system in accordance with the content of an agreement between the stakeholders. A consensus building support tool provides a support for consensus building through an argument regarding an ordinary operation state of a target system. History obtained in the process of the consensus building is recorded in a database layer as an agreement graph. A monitoring node tool detects deviation from the ordinary operation state of the target system based on an actual operation state of the target system and the agreement graph. A contract generating tool extracts information data regarding the consensus building from the agreement graph when the deviation from the ordinary operation state is detected in the target system.


Patent
Symphony | Date: 2013-10-22

The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include spectrum selective kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Innovation Voucher | Award Amount: 5.00K | Year: 2015

Supporting final design of a new British manufactured residential and commercial future proofed charging point that charges any electric vehicle whatever the type of cable used by the car manufacturer. Developed by SYMPHONY CARS LTD in Liverpool, it will complete a range of products by SYMPHONY that will enable the integrated delivery to businesses and the public of everything that the electric vehicle operator needs to get on the road and stay on the road.

Loading Symphony collaborators
Loading Symphony collaborators